

Recombinant Sudan virus Glycoprotein minus the Transmembrane Region (SUDV rGPΔTM)

Catalog #: 0502-001

Lot #: 1311001

Description: Mature, recombinant, HA-tagged Sudan virus Glycoprotein minus the transmembrane domain (SUDV rGPΔTM) is supplied as purified protein. SUDV rGPΔTM is produced in mammalian cells and is purified by FPLC.

Storage: 2-3 weeks at -20°C, -80°C long term


Size: 100 µg of protein is supplied in PBS at a concentration of 1.07 mg/mL. The theoretical molecular weight of the protein is ~110-160 kDa including the HA-tag, without glycosylation. Because of the highly glycosylated nature of this protein, migration in an SDS-PAGE gel is slowed resulting in broad, diffuse bands representing differing glycosylation forms.

Relevance: Recombinant glycoprotein provides a means for antibody development, control protein for testing, and a tool to enhance research.

Western Blot: Quality control testing demonstrates strong detection of GP null and GP1 under reduced conditions down to 50 ng when using IBT's monoclonal antibody 2H5 (cat 0202-029) at 0.5 µg/mL.

Related Products: IBT provides a wide array of anti-filovirus specific antibodies and other infectious disease reagents. Please see our website, www.ibtbioservices.com for more details.

SDS-PAGE & Western Blot Detection



(A) SDS-PAGE and stain demonstrating 1 µg, 5 µg (lane 1, 2 respectively) of SUDV rGPΔTM HA-Tag protein under denaturing and reducing conditions. MW denotes Novex Sharp prestained protein markers. (B) Western blot detection of SUDV rGPΔTM at 50 ng, 100 ng, and 500 ng (lanes 1-3). SUDV rGPΔTM was detected using IBT's monoclonal antibody 2H5 (cat 0202-029) at 0.5 µg/mL and anti-mouse IgG-HRP conjugate, followed by TMB substrate.

ELISA Data

SUDV GPΔTM ng/well	OD 650 nm
800.00	3.332
400.00	3.276
200.00	3.303
100.00	3.366
50.00	3.282
25.00	3.281
12.50	2.496
6.25	1.708

Plate was coated with SUDV rGPΔTM starting at 800 ng/well, serially diluted in DPBS. Washed plate was detected using one dilution of a positive control serum, followed with anti-IgG HRP conjugate and TMB substrate. OD₆₅₀ is reported. Background of SUDV rGPΔTM coated plate without positive control serum was 0.046 OD₆₅₀.

Intended for research use only, not for human, therapeutic, or diagnostic applications.

The buyer cannot sell or otherwise transfer this product for Commercial Purposes without written approval of Integrated BioTherapeutics, Inc.

Copyright 2019. Integrated BioTherapeutics, Inc. All rights reserved.